Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Radioiodine-Unresponsive Thyroid Carcinomas
NCT00287287Phase 2Completed
- Start
- Feb 2006
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in Papillary Thyroid Carcinoma (PTC) and follicular thyroid carcinoma (FTC). Primary endpoint: Response Rate at 4 years. Started Feb 2006; status: completed.
02
Drugs
lenalidomide
03
Conditions
Papillary Thyroid Carcinoma (PTC)follicular thyroid carcinoma (FTC)
Beyond the preview
Go deeper on NCT00287287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00287287.